Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303732 · ClinicalTrials.gov registry record · Phase 1
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Daniel George, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00303732 is a Phase 1 study that has completed, run by Daniel George, MD. The registered enrollment target is 37 participants.
The verdict
NCT00303732, a Phase 1 study, has completed, sponsored by Daniel George, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and everolimus and to see how well they work in treating patients with advanced solid tumors.
Interventions
- DRUG RAD001 (everolimus)
- DRUG PTK787 (vatalanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303732
The ClinicalTrials.gov registry entry for NCT00303732 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daniel George, MD, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RAD001 (everolimus) is the first listed.
NCT00303732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303732 about?
NCT00303732 is a clinical study titled "Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors". RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and everolimus and to see how well they work in ...
What is the current status of trial NCT00303732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2004-12. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00303732?
The interventions under investigation include: RAD001 (everolimus) (DRUG), PTK787 (vatalanib) (DRUG).
Who is sponsoring clinical trial NCT00303732?
This trial is sponsored by Daniel George, MD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.